Technical Analysis for PTLA - Portola Pharmaceuticals, Inc.

Grade Last Price % Change $ Change
grade B $31.68 4.66% 1.41
PTLA closed up 4.66 percent on Friday, February 17, 2017, on 1.11 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Earnings due: Feb 27

Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Very Strong Up Up Up
See historical PTLA trend table...

Date Alert Name Type % Chg
Feb 16 Slingshot Bullish Bullish Swing Setup 4.66%
Feb 16 Calm After Storm Range Contraction 4.66%
Feb 15 Calm After Storm Range Contraction 2.99%
Feb 14 Stochastic Reached Overbought Other 4.59%
Feb 14 Calm After Storm Range Contraction 4.59%
Feb 9 Golden Cross Bullish 16.56%
Feb 9 1,2,3 Pullback Bullish Bullish Swing Setup 16.56%
Feb 9 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 16.56%
Feb 9 Calm After Storm Range Contraction 16.56%
Feb 8 Volume Surge Other 15.83%

Older signals for PTLA ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.

Profile
Portola Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of thrombosis, other hematologic disorders, and inflammation. Its development products include Betrixaban, an oral once-daily inhibitor of Factor Xa, which is in Phase III development trials for the treatment of venous thromboembolism prophylaxis in acute medically ill patients; and PRT4445, a recombinant protein that is in Phase II trials to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or undergo emergency surgery. The company’s products under development also comprise PRT2070, which is in Phase I/II studies to treat B-cell hematologic cancers; and PRT2607 that is in Phase I clinical trials for inflammatory disorders. It has a license and collaboration agreement with Biogen Idec Inc. for the development and commercialization of its clinical-stage product candidates PRT2607; license and collaboration agreement with Aciex Therapeutics, Inc. to co-develop and co-commercialize PRT2070 and related compounds for nonsystemic indications; and an agreement with Astellas Pharma, Inc. to research, develop, and commercialize Syk inhibitors. The company was founded in 2003 and is headquartered in South San Francisco, California.
Is PTLA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 33.28
52 Week Low 15.68
Average Volume 1,313,557
200-Day Moving Average 23.11
50-Day Moving Average 24.45
20-Day Moving Average 27.9
10-Day Moving Average 29.34
Average True Range 1.4
ADX 54.52
+DI 37.23
-DI: 6.82
Chandelier Exit (Long, 3 ATRs) 27.78
Chandelier Exit (Short, 3 ATRs) 28.73
Upper Bollinger Band 31.99
Lower Bollinger Band 23.81
Percent B (%b) 0.96
Bandwidth 0.29319